Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children
Genetic Disorder
Turner Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-05-23

Last Posted Date: 2015-07-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2016

Registration Number: NCT01604161

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Phase 1

Completed

Conditions: Haemostasis
Healthy

Interventions: Drug: clopidogrel
Drug: placebo

First Posted Date: 2012-05-22

Last Posted Date: 2016-11-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01603342

Locations: 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Trauma

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-05-18

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT01601457

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Phase 2

Completed

Conditions: Dengue Haemorrhagic Fever
Acquired Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-05-18

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01601613

Locations: 🇹🇭
Novo Nordisk Investigational Site, Ubonratchathani, Thailand

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: NNC 0148-0000-0362
Drug: insulin glargine
Drug: placebo

First Posted Date: 2012-05-14

Last Posted Date: 2015-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 83

Registration Number: NCT01597713

Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women

Phase 1

Completed

Conditions: Menopause
Healthy

Interventions: Drug: 2 mg estradiol / 1 mg norethisterone acetate (NETA)

First Posted Date: 2012-05-10

Last Posted Date: 2015-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT01596010

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin degludec/insulin aspart

First Posted Date: 2012-05-03

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01590836

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-05-02

Last Posted Date: 2017-07-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 155

Registration Number: NCT01589653

Locations: 🇻🇳
Novo Nordisk Investigational Site, Ho Chi Minh City, Vietnam

Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Completed

Conditions: Haemophilia B With Inhibitors
Haemophilia A With Inhibitors
Congenital Bleeding Disorder

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2012-04-27

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9

Registration Number: NCT01586936

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2012-04-26

Last Posted Date: 2018-02-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3618

Registration Number: NCT01585506

Locations: 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy